Company Engagement

The Medicines Patent Pool’s work depends on partnerships with stakeholders in the field of HIV, hepatitis C and tuberculosis, and its partnerships with patent holding companies are critical to its success.

Following the announcement of MPP’s expansion into hepatitis C and tuberculosis treatment approved by its funder UNTAID in November 2015, the Medicines Patent Pool signed a licensing agreement with Bristol-Myers Squibb (BMS) for hepatitis C medicines daclatasvir (DCV) allowing generic manufacturer to develop and distribute daclatasvir in 112 low- and middle-income countries. The MPP has opened negotiations with the Egyptian drug manufacturer Pharco Pharmaceuticals for the hepatitis C drug candidate ravidasvir.

The MPP also has begun negotiations with a research-based university for sutezolid, a promising treatment for tuberculosis.

The MPP has signed licensing agreements with AbbVie, Bristol-Myers Squibb, Gilead Sciences, Johns Hopkins University, MSD (Merck & Co in the USA and Canada), Roche, ViiV Healthcare [a joint venture of GlaxoSmithKline, Pfizer and Shionogi], the University of Liverpool and the US National Institutes of Health.

The Medicines Patent Pool has also sub-licensed to generic manufacturers, who are already beginning to produce and supply HIV medicines at a lower cost.  As of November 2016, the MPP had signed sub-licensing agreements with fifteen generic manufacturers: Aurobindo Pharma Limited, Beximco, Cipla, Desano, Emcure Pharmaceuticals, Hetero Labs, Huahai Pharmaceutical, Laurus Labs, Lupin, Micro Labs, Mylan, Natco, Sandoz, Strides Arcolab and Zydus Cadila.

The MPP looks forward to continuing dialogue with all relevant patent holders and eligible generic manufacturers and product development partnerships to increase access to medicines for people living in developing countries.

Patent Holder Engagement

Patent Holder 2016 2015 2014 2013 2012 2011 2010
AbbVie Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014 In negotiations Not in negociations Not in negotiations

Reply received 26 January

Sent letter on 1 December
Boehringer-Ingelheim

BI announced the expansion of its non-enforcement policy to create greater access to nevirapine

In negotiations In negotiations In negotiations In negotiations In negotiations

Reply received 19 January

Sent letter on 1 December 
Bristol-Myers Squibb Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013 Licence agreement for atazanavir signed in December 2013 In negotiations In negotiations

Reply received 26 January

Sent letter on 1 December
F. Hoffman-La Roche Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 In negotiations In negotiations Sent letter on 1 December
Gilead Sciences Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 Licence agreement signed in July 2011. Additional amendment made in July 2012 and November 2012 Licence agreement signed in July. Amendments made November 2011. In negotiationsReply received 14 February Sent letter on 1 December
Merck Sharp & Dohme (MSD) Licence agreement for paediatrics signed in February 2015 Licence agreement for paediatrics signed in February 2015 In negotiations Not currently in negotiations Not currently in negotiations Not currently in negotiations. Reply received 28 January Sent letter on 1 December
Janssen Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Not currently in negotiations Not currently in negotiations Not currently in negotiations. J&J decision not to licence at this time Not currently in negotiations. Reply Received 31 January Sent letter on 1 December
Pharco Pharmaceuticals N/A N/A N/A N/A N/A N/A N/A
 Research-based university  N/A  N/A  N/A  N/A  N/A  N/A N/A
 US National Institutes of Health Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir Licence agreement signed in September 2010 for darunavir

In negotiations

Licence agreement signed in September 2010 for darunavir

In negotiations

 Licence agreement signed in September 2010 for darunavir
ViiV Healthcare Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in February 2013 for abacavir In negotiations In negotiations Sent letter on 1 December

 

This page is also available in: French, Spanish